Category
Androgen Receptor Inhibitors ANTI-CANCER API
Androgen Receptor Inhibitors ANTI-CANCER API
Consistent
Purity
Global-Ready
Molecules
Advanced
Manufacturing
Scalable
Production
Partnership
Support
Enzalutamide API has been developed by ASANA Pharmaceutical as part of its specialized line of oncology APIs. Enzalutamide API, with CAS number 915087-33-1, is an advanced androgen receptor inhibitor used in the treatment of castration-resistant prostate cancer.
ASANA Pharmaceutical is focused on the development and production of advanced oncology APIs, including high-purity androgen receptor inhibitors like Enzalutamide. Known for its targeted mechanism in prostate cancer therapy, this compound is manufactured under strict GMP protocols to meet international regulatory expectations. ASANA supports clients across North America, Europe, and Asia with dependable quality, scalability, and scientific precision.
ASANA Pharmaceutical collaborates closely with oncology-focused research groups, CDMOs, and global distribution partners to drive innovation in anti-cancer treatment development. With Enzalutamide [CAS No. 915087-33-1] as a flagship API in its hormone-based therapy segment, ASANA ensures supply continuity for therapies that combat castration-resistant prostate cancer by inhibiting androgen receptor signaling. As oncology care becomes more personalized and global demand intensifies, ASANA remains committed to delivering:
Enzalutamide API are available on public databases such as Wikipidia!